Application of active ingredients of gentiana scabra in preparation of anti-HPV gel

Abstract

The invention discloses an application of an effective component of broom flower in preparing an anti-HPV gel. The effective components in broom flower are combined to prepare an anti-HPV gel. The raw materials for preparing the antibacterial gel include, by mass percentage, 0.5-1.5% of an effective component of broom flower, 0.4-0.6% of anhydride bovine β-lactoglobulin, 0.5-1.5% of carbomer, 8-12% of glycerol, 1-2% of triethanolamine and the remainder of pure water. The gel prepared by the invention does not contain chemical raw materials and ethanol, is mild and non-irritating to the skin, and has obvious therapeutic effect on the treatment of HPV infection.

Description

Technical Field

[0001] The invention belongs to the technical field of medicine, and particularly relates to application of an effective component of gorse flower in preparing an anti-HPV gel. Background Art

[0002] Human papillomavirus (HPV) is a sexually transmitted disease caused by a spherical DNA virus, with humans as its sole reservoir. Studies have found that HPV can be detected in approximately 90% of cervical cancer tissues. High-risk HPV infections, such as HPV16 and HPV18, are closely associated with cervical cancer. It is now widely recognized that HPV infection is a necessary factor for cervical cancer and its precancerous lesions. In particular, the rapid increase in cervical cancer incidence over the past decade has made it a major threat to women's health.

[0003] Currently, HPV vaccines primarily protect against common HPV types, including HPV 16 and 18, but have limited cross-protection against other types. Furthermore, HPV vaccines have no significant therapeutic effect on patients with existing HPV infection or precancerous lesions. Therefore, clinical practice generally considers routine HPV and cervical cytology screening to be more important for diverse populations, enabling early prevention and treatment.

[0004] Currently, there are many treatments for HPV infection, among which topical medication is one of the commonly used methods. There are many types of drugs, but the clinical cure rate is not ideal. Therefore, it is necessary to develop new anti-HPV drugs.

[0005] Parochetus communis, also known as purple broom, is a creeping herbaceous plant of the Fabaceae family and the genus Parochetus. Parochetus extract is a concentrated extract of the Miao medicine parochialis, obtained through hydrothermal extraction (similar to the traditional Chinese medicine decoction method). Research has shown that parochialis is rich in flavonoids, coumarins, saponins, and organic acids. The whole plant, used as medicine, has sour, astringent, and warm properties, nourishing yin, harmonizing blood, and strengthening the spleen. It is used to treat fatigue, cough, dizziness, back pain, asthma, leucorrhea in women, malnutrition in children, mastitis, and traumatic injuries. However, the potential applications of parochialis in Miao medicine have yet to be fully explored. Summary of the Invention

[0006] The purpose of the present invention is to provide a wash-free anti-HPV gel. The anti-HPV gel provided by the present invention does not contain chemical raw materials and ethanol, is mild and non-irritating to the skin, and has obvious therapeutic effects on the treatment of HPV infection.

[0007] In order to solve the above problems, the present invention adopts the following technical solutions:

[0008] The invention discloses an application of broom flower active ingredients in preparing an anti-HPV gel. The active ingredients in broom flower are combined to prepare the anti-HPV gel. The raw materials for preparing the anti-HPV gel include, by mass percentage, 0.5-1.5% of broom flower active ingredients, 0.4-0.6% of acid anhydride bovine beta-lactoglobulin, 0.5-1.5% of carbomer, 8-12% of glycerol, 1-2% of triethanolamine, and the balance of pure water.

[0009] Preferably, the effective ingredient of gorse is gorse extract.

[0010] Preferably, the effective ingredients of the gentiana flower include pterostilbene compounds and caragarin compounds.

[0011] Preferably, the mass ratio of the pterostilbene compound to the caragarin compound is 1:(0.1-10).

[0012] Preferably, the pterosauroid compound is selected from one or more of 3-hydroxy-4,9-dimethoxy pterosauroid, 4,9-dihydroxy-3-methoxy pterosauroid, medipaerol, galangal glucoside and 3-methoxy-8,9-dioxymethylene pterosauroid.

[0013] Preferably, the carrageenan compound is selected from one or both of carrageenan A and carrageenan C.

[0014] Preferably, the mass ratio of the 3-hydroxy-4,9-dimethoxypteroside, 4,9-dihydroxy-3-methoxypteroside, medipteroside, koreana glucoside and 3-methoxy-8,9-dioxymethylenepteroside in the gel is (1-5): (1-6): (1-3.6): (0.6-2.4): (0.5-1.8).

[0015] Preferably, the mass ratio of carrageenan A to carrageenan C in the gel is 1:(0.2-5).

[0016] The present invention also provides a method for preparing the anti-HPV gel, which specifically comprises the following steps:

[0017] (1) Mix carbomer and glycerin according to the ratio and stir until they become a paste;

[0018] (2) The active ingredients of gentiana floridula, acid anhydride-treated bovine β-lactoglobulin and pure water are stirred evenly, and the obtained liquid is added to the paste of step (1) under stirring conditions, stirred evenly, and then triethanolamine is added and dispersed evenly to obtain the anti-HPV gel.

[0019] The isoelectric point of bovine β-lactoglobulin is between 4.5 and 5.5. 3-Hydroxyphthalic anhydride is generally strongly acidic, and bovine β-lactoglobulin contains basic amino acid residues on its peptide chain. 3-Hydroxyphthalic anhydride can modify the basic amino acids on bovine β-lactoglobulin, altering the original surface charge distribution and increasing the negative charge of bovine β-lactoglobulin. This anhydride-modified bovine β-lactoglobulin is called anhydride-modified bovine β-lactoglobulin. Human papillomavirus (HPV) is a small DNA virus whose viral gene is a double-stranded circular DNA with a positive surface charge. The negative charge on the anhydride-modified bovine β-lactoglobulin can complex with the positive charge on the HPV surface, inactivating the HPV protein.

[0020] Carbomer, also known as polyacrylic acid, is typically a loose white powder and an excellent gel matrix. Carbomer is a high-molecular-weight polymer composed of acrylic acid bonded to allyl sucrose or pentaerythritol allyl ether. It exhibits a certain degree of acidity. By properly adjusting the pH of the carbomer solution, the carbomer molecules, acting as carboxyl donors, can form hydrogen bonds with one or more carboxyl groups, causing the coiled molecules to open due to electrical repulsion and thicken. As the macromolecules gradually dissolve, the viscosity increases, forming a clear solution at low concentrations and a translucent gel at high concentrations. Consequently, carbomer exhibits excellent adhesiveness and film-forming properties, making it a common raw material for gynecological gels used in medical devices.

[0021] Glycerin, also known as propylene glycol, is a colorless, odorless, clear, concentrated liquid with a tangy flavor. Typically extracted from oils and fats, glycerin is highly hygroscopic. When applied to the skin, it forms a thin layer that insulates against air and prevents evaporation. It also absorbs moisture from the air, helping to regulate the gel's shape.

[0022] Broom is rich in flavonoids, coumarins, saponins, and organic acids. Broom extracts are known to have significant antibacterial effects. This study combined the active ingredients of Broom with bovine β-lactoglobulin and other raw materials to prepare a gel for its application in the fight against HPV.

[0023] Beneficial effects of the present invention:

[0024] The invention combines the effective components of gorse with bovine beta-lactoglobulin to prepare the anti-HPV gel. The prepared gel does not contain chemical raw materials and ethanol. Clinical trials have shown that the gel of the invention has obvious therapeutic effects on HPV infection. DETAILED DESCRIPTION

[0025] 1. Preparation of Broom Extract

[0026] The broom flower is dried and crushed, and then passed through a 40-100 mesh sieve. It is then cold-soaked in a 70% methanol aqueous solution for three times, each time for three days. The filtrates are combined, and the solvent is recovered under reduced pressure to obtain the broom flower extract.

[0027] 2. Preparation of compounds from the active ingredients of gorse

[0028] 1. Extraction: Dry and crush the gorse flower, then pass through a 40-100 mesh sieve. Cold-soak the gorse flower in a 70% methanol-water solution three times, each for three days. Combine the filtrates and recover the solvent under reduced pressure to obtain the gorse flower extract. Disperse the gorse flower extract with 1.5 times its volume of water, then extract with equal amounts of petroleum ether, ethyl acetate, and n-butanol, respectively. Recover the solvent to obtain the petroleum ether fraction, ethyl acetate fraction, and n-butanol fraction, respectively.

[0029] 2. Separation: Dissolve the petroleum ether and ethyl acetate fractions in methanol and filter to obtain a precipitate, fraction e. Place this precipitate in a 500 mL round-bottom flask and perform a classic acetylation derivatization reaction (add 300 mL of pyridine and excess acetic anhydride and stir overnight at room temperature). After the reaction, add a small amount of citric acid to neutralize the pyridine. Extract with ethyl acetate to obtain product f. Dissolve product f in chloroform and add silica gel for mixing. Apply the sample to a silica gel H column and elute with chloroform / methanol (volume ratios of 100:1, 50:1, and 25:1). Identify and combine the same components by thin-layer chromatography to obtain fractions fr.1 and fr.2. Fraction fr.1 was purified by repeated silica gel column chromatography and Sephadex LH-20 to yield compounds I and II. Fraction fr.2 was purified by silica gel H column eluting with chloroform / methanol (volume ratios 25:1, 15:1). Identical fractions were combined by thin-layer chromatography to yield fractions fc.1 to fc.2. Fraction fc.1 was purified by silica gel H column eluting with chloroform / methanol (volume ratios 100:1, 50:1) to isolate compound III. Fraction fc.2 was separated into four fractions. The first fraction was purified by Sephadex LH-20 column chromatography to yield compound IV. The second fraction was purified by Sephadex LH-20 column chromatography to yield compound V. The third fraction was purified by Sephadex LH-20 column chromatography eluting with chloroform / methanol (volume ratio 70:30) to yield compound VI. The fourth segment was separated by Sephadex LH-20 gel column chromatography and eluted with chloroform / methanol (volume ratio 90:10) to obtain compound VII.

[0030] 3. Purification: Dissolve the compound obtained above in methanol and obtain the pure compound by preparative liquid chromatography.

[0031] Preparative column: Robusta C18 (250 mm × 4.6 mm, 10 μL), gradient elution with methanol (A)-0.1% acetic acid water (B), 0-5 min, A: 20%; 5-40 min, A: 20%-80%; column temperature 35°C; wavelength 280 nm.

[0032] 4. Identification of compounds:

[0033] (1) Dissolve the compound sample in methanol and analyze it by gas chromatography-liquid chromatography (GC) and mass spectrometry (MS).

[0034] (2) Analysis conditions

[0035] GC conditions: A quartz capillary column HP-FFAP (30 m × 0.25 mm × 0.25 μm) was programmed to heat from 40°C for 3 min, then to 120°C at a rate of 5°C / min and held for 2 min, then to 6°C / min until the analysis was complete. The carrier gas was He (99.99%), and the column flow rate was 1.0 μL / min.

[0036] MS conditions were: EI source, electron energy 70 eV, interface temperature 230 °C, ion source temperature 230 °C, solvent delay time 2.5 min, and scanning range 35–550 μm.

[0037] 5. Conclusion

[0038] Compound Ⅰ was identified as 3-hydroxy-4,9-dimethoxypterocarpin;

[0039] Compound II was identified as 4,9-dihydroxy-3-methoxypterocarpin;

[0040] Compound III was identified as meditartin;

[0041] Compound IV was identified as 3-methoxy-8,9-dioxymethylene pterostilbene;

[0042] Compound V was identified as Sophora japonica glucoside;

[0043] Compound VI was identified as caragarin A;

[0044] Compound VII was identified as caragarin C.

[0045] The specific structural formula of the above compound is as follows:

[0046]

[0047] .

[0048] 3. Application of the active ingredient of the present invention in the preparation of anti-HPV gel

[0049] Example 1:

[0050] This embodiment provides an anti-HPV gel, the raw materials for its preparation are:

[0051] .

[0052] The preparation method specifically comprises the following steps:

[0053] (1) Mix carbomer and glycerin according to the ratio and stir until they become a paste;

[0054] (2) The active ingredient of gentiana (gentiana extract), acid anhydride-modified bovine β-lactoglobulin and pure water are stirred evenly, and the obtained liquid is added to the paste liquid of step (1) under stirring conditions, stirred evenly, and then triethanolamine is added and dispersed evenly to obtain the anti-HPV gel.

[0055] Example 2:

[0056] This embodiment provides an anti-HPV gel, the raw materials for its preparation are:

[0057] .

[0058] Among them, the ratio of pterostilbene compounds to caragarin compounds is arbitrary (1 / 0.05); caragarin A / caragarin C=1 / 0.2.

[0059] The preparation method specifically comprises the following steps:

[0060] (1) Mix carbomer and glycerin according to the ratio and stir until they become a paste;

[0061] (2) The active ingredients of gentiana (3-hydroxy-4,9-dimethoxypterocarpon, caragarin A, caragarin C), anhydride-treated bovine β-lactoglobulin and pure water are stirred evenly, and the obtained liquid is added to the paste of step (1) under stirring conditions, stirred evenly, and then triethanolamine is added and dispersed evenly to obtain the anti-HPV gel.

[0062] Example 3:

[0063] This embodiment provides an anti-HPV gel, the raw materials for its preparation are:

[0064] .

[0065] The ratio of pterostilbene compound to caragarin compound is 1 / 11, and caragarin A / caragarin C is 1 / 0.2. The rest of the preparation method is the same as that of Example 2.

[0066] Example 4:

[0067] This embodiment provides an anti-HPV gel, the raw materials for its preparation are:

[0068] .

[0069] Among them, pterostilbene compounds / caragarin compounds = 1 / 2;

[0070] 3-Hydroxy-4,9-dimethoxy-pterocarpin / 4,9-dihydroxy-3-methoxy-pterocarpin / medioside / sophora japonica glucoside / 3-methoxy-8,9-dioxymethylene-pterocarpin are in an arbitrary ratio (1 / 1 / 1 / 1 / 1).

[0071] The ratio of carrageenan A to carrageenan C is 1 / 0.1.

[0072] The preparation method specifically comprises the following steps:

[0073] (1) Mix carbomer and glycerin according to the ratio and stir until they become a paste;

[0074] (2) The active ingredients of gentiana flower (3-hydroxy-4,9-dimethoxypterocarpon, 4,9-dihydroxy-3-methoxypterocarpon, medipterocarpon glycoside, Korean locust glucoside, 3-methoxy-8,9-dioxymethylenepterocarpon, caragarin A, caragarin C), anhydride-treated bovine β-lactoglobulin and pure water are stirred evenly, and the obtained liquid is added to the paste of step (1) under stirring conditions, stirred evenly, and then triethanolamine is added and dispersed evenly to obtain the anti-HPV gel.

[0075] Example 5:

[0076] This embodiment provides an anti-HPV gel, the raw materials for its preparation are:

[0077] .

[0078] Among them, the ratio of pterostilbene compounds / caragarin compounds = 1 / 10; caragarin A / caragarin C = 1 / 0.2.

[0079] The preparation method specifically comprises the following steps:

[0080] (1) Mix carbomer and glycerin according to the ratio and stir until they become a paste;

[0081] (2) The active ingredients of gentiana (3-hydroxy-4,9-dimethoxypterocarpon, caragarin A, caragarin C), anhydride-treated bovine β-lactoglobulin and pure water are stirred evenly, and the obtained liquid is added to the paste of step (1) under stirring conditions, stirred evenly, and then triethanolamine is added and dispersed evenly to obtain the anti-HPV gel.

[0082] Example 6:

[0083] This embodiment provides an anti-HPV gel, the raw materials for its preparation are:

[0084] .

[0085] Among them, pterostilbene compounds / caragarin compounds = 1 / 4;

[0086] 4,9-dihydroxy-3-methoxypteroside / medipteroside / sophora japonica glucoside=3.5 / 2.3 / 1.4.

[0087] The preparation method specifically comprises the following steps:

[0088] (1) Mix carbomer and glycerin according to the ratio and stir until they become a paste;

[0089] (2) The active ingredients of gentiana (4,9-dihydroxy-3-methoxypterocarpon, medipterocarpon glycoside, karaginol A), anhydride-modified bovine β-lactoglobulin and pure water are stirred evenly, and the obtained liquid is added to the paste of step (1) under stirring conditions, stirred evenly, and then triethanolamine is added and dispersed evenly to obtain the anti-HPV gel.

[0090] Example 7:

[0091] This embodiment provides an anti-HPV gel, the raw materials for its preparation are:

[0092] .

[0093] Among them, pterostilbene compounds / caragarin compounds = 1 / 2;

[0094] 3-Hydroxy-4,9-dimethoxy-pterocarpin / 4,9-dihydroxy-3-methoxy-pterocarpin / medioside / sophora japonica glucoside / 3-methoxy-8,9-dioxymethylene-pterocarpin=1 / 1 / 1 / 0.6 / 0.5.

[0095] Karagesu A / Karaagesu C=1 / 5.

[0096] The rest of the preparation method is the same as Example 4.

[0097] Example 8:

[0098] This embodiment provides an anti-HPV gel, the raw materials for its preparation are:

[0099] .

[0100] Among them, pterostilbene compounds / caragarin compounds = 1 / 0.1;

[0101] 3-Hydroxy-4,9-dimethoxy-pterocarpin / 4,9-dihydroxy-3-methoxy-pterocarpin / medioside / sophora japonica glucoside / 3-methoxy-8,9-dioxymethylene-pterocarpin=5 / 6 / 3.6 / 2.4 / 1.8.

[0102] The preparation method specifically comprises the following steps:

[0103] (1) Mix carbomer and glycerin according to the ratio and stir until they become a paste;

[0104] (2) The active ingredients of gentiana flower (3-hydroxy-4,9-dimethoxypterocarpon, 4,9-dihydroxy-3-methoxypterocarpon, medipterocarpon glycoside, korean locust glucoside, 3-methoxy-8,9-dioxymethylenepterocarpon, caragacin C), anhydride-treated bovine β-lactoglobulin and pure water are stirred evenly, and the obtained liquid is added to the paste of step (1) under stirring conditions, stirred evenly, and then triethanolamine is added and dispersed evenly to obtain the anti-HPV gel.

[0105] Comparative Example 1:

[0106] This comparative example provides an anti-HPV gel, which differs from Example 1 in that the mass of the broom flower extract is 0.3 g, and the mass of the anhydride-treated bovine β-lactoglobulin is 0.2 g.

[0107] Comparative Example 2:

[0108] This comparative example provides an anti-HPV gel, which differs from Example 1 in that the mass of the broom flower extract is 2 g, and the mass of the anhydride-treated bovine β-lactoglobulin is 1 g.

[0109] 3. In vitro cytotoxicity of the anti-HPV gel of the present invention

[0110] 1. Reference standard: GB / T16886.5-2017 / ISO 10993-5:2009 “Biological evaluation of medical devices—Part 5: In vitro cytotoxicity tests”.

[0111] 2. Preparation of test and reference substances

[0112] (1) Preparation of test sample: 1 g of the anti-HPV gel prepared in the present invention was added to 10 mL of extraction medium, and the mixture was placed in a carbon dioxide incubator at 37 ± 1 °C for 24 hours to prepare a sample extract. The extract was diluted in a ratio of 1:2 for testing.

[0113] (2) Preparation of blank control sample: Place the same batch of extraction medium in a carbon dioxide incubator at 37±1℃ for 24 hours to prepare blank control solution.

[0114] (3) Preparation of negative control: Take high-density polyethylene resin (batch number P25141125, manufacturer: Shandong Yousuo Chemical Technology Co., Ltd.), wash it with ultrapure water, sterilize it at 121℃ for 30 minutes, add the same batch of extraction medium at a ratio of 0.2g / mL, place it in a carbon dioxide incubator at 37±1℃ for 24 hours, and prepare a negative control solution.

[0115] (4) Preparation of positive control: Take dimethyl sulfoxide (batch number 20201202, manufacturer: Sinopharm Chemical Reagent Co., Ltd.), filter and sterilize, take 0.5 mL, add 9.5 mL of extraction medium, place in a carbon dioxide incubator at 37±1℃ for 24 hours, and prepare the positive control solution.

[0116] 3. Test methods

[0117] L929 cells that have been cultured for 72 hours and are growing vigorously were taken and digested with 0.25% trypsin solution and then added into cell culture medium RPMI-1640. After pipetting and mixing, the cells were counted under a microscope and the cell suspension was prepared to a density of 1×10 5 Pipette 2 mL of cell suspension into the culture dish and culture in a CO2 incubator at 37 ± 1°C until a nearly confluent cell monolayer is formed.

[0118] Discard the original culture medium, add the sample solution of blank group, negative control group, positive control group and test sample group respectively, aspirate 2 mL each and inject into the culture dish, and culture in a carbon dioxide incubator at 37±1℃ for 24 hours.

[0119] 4. Test results

[0120] After the culture was completed, the cell changes were observed under a microscope. When the cytotoxicity grade was greater than grade 2, it was considered to have a cytotoxic effect. The results are shown in Table 1 below.

[0121] Table 1

[0122]

[0123] From the results in Table 1 above, it can be seen that the cytotoxicity of the anti-HPV gel of the present invention is graded as Level 2, the reaction degree is mild, and it has no cytotoxic effect.

[0124] IV. Clinical anti-HPV effect of the anti-HPV gel of the present invention

[0125] 1. Test subjects

[0126] Inclusion criteria: ① Women aged 18 years or older with a history of sexual activity; ② No gynecological treatment in the past 3 months; ③ Positive for high-risk HPV16 and / or 18 infection (detected by the HC2 method, a value greater than 1.0 is considered positive).

[0127] Exclusion criteria: ① history of cervical cancer and precancerous lesions; ② pregnant and lactating women; ③ history of related drug allergies; ④ immune system diseases or severe heart, liver, or kidney dysfunction.

[0128] 2. Test methods

[0129] The patients were randomly divided into observation groups 1 to 10 (treated with the anti-HPV gel prepared in Examples 1 to 8 and Comparative Examples 1 and 2, respectively) and a control group (treated with Baofukang suppositories), with 50 cases in each group. The average age of the observation group was (32.35 ± 4.12) years, the average number of births was (2.16 ± 1.12), and the average body mass index (BMI) was (25.98 ± 3.26) kg / m 2 The average age of the control group was (33.01±5.31) years, the number of births was (2.23±1.34), and the average body mass index (BMI) was (26.30±2.99) kg / m 2 There was no statistically significant difference in the mean age, number of parities, and BMI between the two groups (P>0.05). Patients in the observation group washed their vaginas with warm water every night and then administered 2-4 g of the gels prepared in Examples 1-9 and Comparative Examples 1 and 2 vaginally.

[0130] 3. Efficacy comparison method

[0131] After treatment, patients in different groups were examined for HPV16 and 18 subtype infections at one month and six months respectively.

[0132] Efficacy criteria: Cure: HC2 value less than 1.0; Ineffectiveness: HC2 value less than 1.0. Effective rate = number of cured cases / total number of cases × 100%.

[0133] 4. Test results

[0134] Table 2

[0135]

[0136] Note: * Indicates P < 0.05 compared with the control group.

[0137] As can be seen from the results in Table 2 above, in the follow-up examination one month after treatment, the total effective rate of HPV infection treatment for patients in observation groups 1 to 8 (Examples 1 to 8) was 80.00% to 88.00%, and the total effective rate for patients in the control group was 44.00%; in the follow-up examination six months after treatment, the total effective rate of treatment for patients in observation groups 1 to 8 was 82.00% to 88.00%, and the total effective rate for patients in the control group was 52.00%.

[0138] It can be seen that the treatment efficacy of HPV infection in patients 1 to 8 in the observation group was higher than that in the control group when reviewed 1 month and 6 months after the end of treatment, and the differences were statistically significant (P < 0.05).

[0139] Among them, the therapeutic effects of observation groups 5 to 8 were more obvious and performed excellently. Compared with Example 1, the therapeutic effects of observation groups 9 and 10 (Comparative Examples 1 and 2) were significantly reduced after the mass of the broom extract and acid-anhydride-treated bovine β-lactoglobulin was changed, indicating that the mass ratio of the two raw materials is specific.

[0140] The above description is merely a preferred embodiment of the present invention and does not limit the technical scope of the present invention. Therefore, any minor modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention still fall within the scope of the technical solution of the present invention.

Claims

1. An application of an effective ingredient of gentiana strychnifolia in the preparation of an anti-HPV gel, characterized in that: The active ingredients in broom are combined to prepare an anti-HPV gel, wherein the raw materials for preparing the anti-HPV gel include, by mass percentage, 0.5-1.5% of active ingredients in broom, 0.4-0.6% of acid anhydride bovine β-lactoglobulin, 0.5-1.5% of carbomer, 8-12% of glycerol, 1-2% of triethanolamine and the balance of pure water; The effective ingredient of the broom flower is a broom flower extract; The preparation method of the broom flower extract comprises: drying and crushing the broom flower, passing through a 40-100 mesh sieve, and then cold-immersing the broom flower in a 70% methanol aqueous solution for three times, each time for three days, combining the filtrates, and recovering the solvent under reduced pressure to obtain the broom flower extract.

2. The use of the effective ingredient of Flos Gerberae according to claim 1 in preparing anti-HPV gel, characterized in that: The broom flower extract comprises pterostilbene compounds and caragarin compounds.

3. The use of the effective ingredient of Flos Gerberae according to claim 2 in the preparation of anti-HPV gel, characterized in that: The mass ratio of the pterostilbene compound to the caragarin compound is 1:(0.1-10).

4. The use of the effective ingredient of Flos Gerberae according to claim 2 in the preparation of anti-HPV gel, characterized in that: The pterostilbene compound is selected from one or more of 3-hydroxy-4,9-dimethoxypterostilbene, 4,9-dihydroxy-3-methoxypterostilbene, medipaerol, korean pterostilbene glucoside and 3-methoxy-8,9-dioxymethylenepterostilbene.

5. The use of the effective ingredient of Flos Gerberae according to claim 2 in preparing anti-HPV gel, characterized in that: The carrageenan compound is selected from one or two of carrageenan A and carrageenan C.

6. The use of the effective component of Flos Gerberae according to claim 4 in the preparation of anti-HPV gel, characterized in that: The mass ratios of the 3-hydroxy-4,9-dimethoxypterocarpon, 4,9-dihydroxy-3-methoxypterocarpon, medipterocarpon glycoside, pagoda tree glucoside and 3-methoxy-8,9-dioxymethylenepterocarpon in the gel are (1-5):(1-6):(1-3.6):(0.6-2.4):(0.5-1.8).

7. The use of the effective component of Flos Gerberae in the preparation of anti-HPV gel according to claim 5, characterized in that: The mass ratio of carrageenan A to carrageenan C in the gel is 1:(0.2-5).

8. A method for preparing the anti-HPV gel according to any one of claims 1 to 7, characterized in that: The specific steps include: (1) Mix carbomer and glycerin according to the ratio, and stir to disperse into a paste; (2) The active ingredients of Broom Flower, acid anhydride-modified bovine β-lactoglobulin and pure water are stirred evenly, and the obtained liquid is added to the paste liquid of step (1) under stirring conditions, stirred evenly, and then triethanolamine is added and dispersed evenly to obtain the anti-HPV gel.

Images